Global Visceral Pain Market Growth (Status and Outlook) 2023-2029

Global Visceral Pain Market Growth (Status and Outlook) 2023-2029

Visceral pain is pain that results from the activation of nociceptors of the thoracic, pelvic, or abdominal viscera (organs). Visceral structures are highly sensitive to distension (stretch), ischemia and inflammation, but relatively insensitive to other stimuli that normally evoke pain such as cutting or burning. Visceral pain is diffuse, difficult to localize and often referred to a distant, usually superficial, structure. It may be accompanied by symptoms such as nausea, vomiting, changes in vital signs as well as emotional manifestations. The pain may be described as sickening, deep, squeezing, and dull. Distinct structural lesions or biochemical abnormalities explain this type of pain in only a proportion of patients. These diseases are grouped under gastrointestinal neuromuscular diseases (GINMD). Others can experience visceral pains, often very intense in nature, without any evidence of structural, biochemical or histolopathologic reason for such symptoms. These diseases are grouped under functional gastrointestinal disorders (FGID) and the pathophysiology and treatment can vary greatly from GINMD. The two major single entities among functional disorders of the gut are functional dyspepsia and irritable bowel syndrome.

LPI (LP Information)' newest research report, the “Visceral Pain Industry Forecast” looks at past sales and reviews total world Visceral Pain sales in 2022, providing a comprehensive analysis by region and market sector of projected Visceral Pain sales for 2023 through 2029. With Visceral Pain sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Visceral Pain industry.

This Insight Report provides a comprehensive analysis of the global Visceral Pain landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Visceral Pain portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Visceral Pain market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Visceral Pain and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Visceral Pain.

The global Visceral Pain market size is projected to grow from US$ 967.9 million in 2022 to US$ 1259.9 million in 2029; it is expected to grow at a CAGR of 3.8% from 2023 to 2029.

Growing focus on research and development by pharmaceutical companies and government initiatives are expected to boost the visceral pain industry over the forecast period. The market is projected to witness significant gain during the forecast period owing to increasing collaboration within pharmaceutical companies. Moreover, growth in the interest of scientists and researchers in studying the pain originating from internal organs has mirrored in the consciousness of the importance of visceral pain in patients. Asia Pacific is expected to grow at the highest CAGR of 6.2% from 2017 to 2024. North America has been leading the market for visceral pain, it is expected that African countries will witness exponential growth during the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of Visceral Pain market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Analgesics
Pain Modifiers

Segmentation by application
Interstitial Cystitis
Crohn’s
Irritable Bowel
Chronic Prostatitis

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Johnson & Johnson
Abbvie
Takeda
Allergan
AstraZeneca

Please note: The report will take approximately 2 business days to prepare and deliver.